Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Aegis Capital Corp.
IAC/InterActiveCorp. Is A Top SMID Idea For 2017
Aegis Capital Believes Valeant Pharmaceuticals' Bid For Allergan Is Looking More Promising
Aegis Capital Believes Seragon Deal Underscores Value In Medivation
Aegis Capital Believes Valeant Pharmaceuticals' Bid For Allergan Is Looking More Promising
Aegis Capital Believes Seragon Deal Underscores Value In Medivation
UPDATE: Aegis Capital Initiates Coverage on Evoke Pharma on Attractive Valuation
Aegis Capital Reiterates on TrovaGene Following In-Line Revenue, Below-Estimates EPS
UPDATE: Aegis Capital Initiates Coverage on Evoke Pharma on Attractive Valuation
Aegis Capital Reiterates on TrovaGene Following In-Line Revenue, Below-Estimates EPS
UPDATE: Aegis Capital Reiterates on Cancer Genetics Following Better-Than-Expected 3Q 2013 Financial Results
UPDATE: Aegis Capital Initiates Coverage on QLogic on Market Leader Position
Read More...
Aegis Capital Corp. Recent News
UPDATE: Aegis Capital Reiterates on Synergy Pharmaceuticals on Approaching Clinical Catalysts
UPDATE: Aegis Capital Reiterates on Medivation Following In-Line 3Q 2013 Financial Results
UPDATE: Aegis Capital Reiterates on Stemline Therapeutics Ahead of ASH Annual Meeting
UPDATE: Aegis Capital Reiterates on TrovaGene Ahead of 3Q 2013 Earnings Report
UPDATE: Aegis Capital Reiterates on Inovio Pharmaceuticals Following Solid 3Q 2013 Results
UPDATE: Aegis Capital Reiterates on Navidea Biopharmaceuticals Following 3Q 2013 Earnings Report
Aegis Capital Reiterates on Sinovac Biotech Following Solid 3Q 2013 Financial Results
Aegis Capital Corp. Reiterates on Amarin Corporation plc After FDA Formally Rescinds Special Protocol Assessment
UPDATE: Aegis Capital Downgrades Amarin Following Negative Panel Vote on Vascepa
Aegis Capital Reiterates Buy on Amarin Corporation Following Release of Vascepa Briefing Documents
UPDATE: Aegis Capital Reiterates Buy Rating, Raises PT on Neuralstem
UPDATE: Aegis Capital Reiterates Buy Rating, Raises PT on China Biologic Products
UPDATE: Aegis Capital Initiates Coverage on Venaxis with Buy Rating, $6 PT
Aegis Capital Reiterates Buy Rating, $25 PT on Synergy Pharmaceuticals
Aegis Capital Reiterates Buy Rating, $25 PT on Synergy Pharmaceuticals
Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation
UPDATE: Aegis Capital Initiates Coverage on Sinovac Biotech with Hold Rating, $2.50 PT
UPDATE: Aegis Capital Initiates Coverage on TrovaGene with Buy Rating, $12 PT
UPDATE: Aegis Capital Initiates Coverage on China Cord Blood Corp. with Buy Rating, $5 PT
UPDATE: Aegis Capital Initiates Coverage on China Biologic Products with Buy Rating, $20 PT
UPDATE: Aegis Capital Corp. Initiates Coverage on Galena Biopharma with Buy Rating, $6 PT
UPDATE: Aegis Capital Initiates Coverage on Trius Therapeutics with Buy Rating, $15 PT